Stay updated with breaking news from Smart Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MILLIONS of customers of a "green" plan are set to claim back up to a decade's worth of premiums paid on energy bills after forking out extra despite
Dan Drogman The UK government is expanding its campaign to persuade British businesses to commit to the country’s net-zero-by-2050 target. But is that enough? Historically, it has not been easy to make meaningful changes at pace and many have been vocal about how difficult it is to reach these targets due to the time it takes and the investment required. That is why there must be more of a concerted effort to implement smart building technology. Most buildings can be reimagined to adopt cutting-edge green technology, which not only supports reaching net zero targets but generates significan...
Crocs Pops 11% After 1Q Results Beat Expectations Priti Ramgarhia- April 27, 2021, 10:22 AM EDT SHARE ON: Shares of Crocs jumped 11% in the pre-market session on Tuesday as the shoe manufacturing company posted strong 1Q results. Record revenue growth of 64% along with outstanding performance in all regions and channels drove the stellar performance. Crocs’ ( CROX) 1Q adjusted earnings of $1.49 per share surged significantly on a year-over-year basis and outpaced the Street estimates of $0.89 per share. Revenues jumped 64% to $460.1 million,...
Shrilekha Pethe- April 26, 2021, 10:54 AM EDT SHARE ON: Inovio said on Friday that the biotechnology company focused on deoxyribonucleic acid (DNA) medicine is planning to conduct the Phase-3 trial of its COVID-19 vaccine candidate, INO-4800, outside the United States. Inovio ( INO) also said that the US Government’s Department of Defense (DoD) will discontinue the funding for the Phase-3 trial of the vaccine, but will continue the funding of the currently ongoing Phase-2 segment of the trial. According to Inovio, the Defense Joint Program Executive Offi...
Shrilekha Pethe- April 26, 2021, 11:55 AM EDT SHARE ON: Shares of Ocugen Inc shot up by 15.6% in pre-market trading on Monday as the company announced the sale of 10 million shares to institutional investors focused on healthcare at a purchase price of $10 per share in a registered direct offering. Ocugen ( OCGN), a gene therapy company that aims to cure blindness, is set to close the direct offering on April 27 and it expects gross proceeds of $100 million from this offering. The company intends to use the net proceeds for working capital needs, general c...